Episodios

  • 115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis

    115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis
    Jul 31 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Michael Weiss, chief executive officer of TG Therapeutics, discussed ublituximab (Briumvi), a recently approved anti-CD20 therapy for relapsing multiple sclerosis, and the advantages it brings to patients. Specifically, he talked about the Department of Veteran Affairs' decision to award national contract to ublituximab as the preferred anti-CD20 for this patient population, and how this facilitates greater access to the treatment. In addition, he discussed how the knowledge profile of the agent has grown over time, as well as the additional efforts to gain a better understanding of its efficacy and safety. Furthermore, he spoke on the differences between ublituximab and other approved agents, and why it may be more applicable to certain patients.

    Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page.

    Episode Breakdown:
    • 1:05 – Significance of ublituximab awarded national contract as preferred anti-CD20 for relapsing MS
    • 3:30 – Advantages and differences of ublituximab vs approved therapies for MS
    • 11:40 – Neurology News Minute
    • 14:30 – Growing knowledge profile of ublituximab over the years
    • 19:05 – Future plans of ubtlituximab; long-term goals of the therapy

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Eli Lilly Announces Date for Donanemab FDA AdComm Hearing
    • Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne
    • ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    26 m
  • 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

    120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
    Jul 26 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Douglas Wajda, PhD, an assistant professor of neurology at Cleveland State University, discussed a pilot study presented at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting using a functional electrical stimulation approach, Neural Sleeve, to treat gait in MS. Wajda, who has been studying gait in MS for several years, gave clinical insight on the functionality and feasibility of this approach, and the personalized treatment patients can gain from it. He also discussed the pilot study in detail, including the major end points and takeaways from the small group of patients observed.


    Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

    Episode Breakdown:
    • 1:00 – Functionality of Neural Sleeve
    • 2:45 – Feasibility and self-administration of Neural Sleeve
    • 3:50 – Neurology News Minute
    • 5:50 – Greatest clinical takeaways from pilot study
    • 8:15 – Steps in advancing this therapeutic approach
    • 9:45 – Challenges with gait in MS and personalizing treatment methods

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Gene Therapy LX2006 Positively Impacts Cardiac Biomarkers of Friedreich Ataxia, Clinical Data Show
    • Buntanetap Transitioning to Crystal Form Following FDA Go-Ahead
    • Endo Voluntarily Recalls One Lot of Clonazepam Tablets Following Mislabeling Error

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    14 m
  • 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease

    119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
    Jul 12 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease (PD). She gave an overview of how the test is utilized in clinic, ways to interpret results, and the right personnel needed to ensure an accurate diagnosis. In addition, she provided clarity on the role of alpha-synuclein in PD, the advances in research in this area, and how the test incorporates this prominent biomarker. Furthermore, Husain-Wilson detailed some of the next steps in further optimizing the test in clinical settings, highlighting the importance of other non-movement disorder specialists who will play a major role in the diagnostic evaluation of future patients with PD.


    Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page.

    Episode Breakdown:
    • 1:10 – Step by step process on how Syn-One test is used; considerations after process is done
    • 3:15 – How the test differentiates PD from other neurodegenerative disorders
    • 9:50 – Neurology News Minute
    • 12:20 – Value and role in assessing alpha-synuclein in PD
    • 14:50 – Ways to further optimize Syn-One going forward

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease
    • Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study
    • Gene Therapy AMT-130 Slows Huntington Disease Progression in Interim Phase 1/2 Trials

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    20 m
  • FDA Approves Donanemab for Early Symptomatic Alzheimer Disease

    FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
    Jul 9 2024
    Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

    In this episode, we're covering the recent approval of donanemab as a new treatment for adults with early symptomatic Alzheimer disease (AD). Marketed as Kisunla, donanemab's approval marks the third antiamyloid therapy to get FDA greenlight for early-stage AD, following the controversial approval of aducanumab (Aduhelm; Biogen) in 2021 and lecanemab (Leqembi; Eisai) in 2023. Donanemab, administered as a 350 mg/20 mL once-monthly injection for intravenous infusion, had its approval supported by the phase 3 TRAILBLAZER-ALZ-2 trial (NCT04437511), a large-scale, double-blind, placebo-controlled trial that featured 1736 patients with early-stage AD. Following the approval, NeurologyLive sat down with Joel Salinas, MD, MBA, a behavioral neurologist at NYU Langone and clinical assistant professor in the department of neurology at the NYU Grossman School of Medicine. Salinas, who also serves as the chief medical officer at Isaac Health, discussed the positive impacts of the approval, the importance of patient selection for the medication, and how clinicians should discuss its benefits and harms to patients. In addition, he commented on how approvals like donanemab continue to carry momentum in the AD field going forward.


    For more of NeurologyLive's coverage of donanemab's approval, head here: FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease
    Episode Breakdown:
    • 2:10 – Positive downstream impacts of donanemab's approval
    • 4:20 – Considerations and caution with prescribing donanemab
    • 6:05 – Salinas on patient-clinician conversations about AD treatments
    • 8:00 – Closing remarks and continued progress in AD field

    Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    11 m
  • 118: Gaining Patient Perspectives on Impact of Narcolepsy

    118: Gaining Patient Perspectives on Impact of Narcolepsy
    Jun 28 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Anne Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, sat down at the 2024 SLEEP Annual Meeting to discuss a poster presentation highlighting a listening analysis that characterized the struggles and unmet needs of people with narcolepsy. in the discussion, Morse outlined some of the major findings, including the rates of missed and misdiagnosis, how cataplexy impacts daily life, and some of the other comorbidities associated with the condition. She spoke on the value of gaining patient perspectives and using their descriptions for their disorders helps in understanding true unmet needs. Furthermore, she spoke on the importance of a strong patient-clinician relationship, the ability to communicate openly, and the steps following diagnosis to ensure effective long-term treatment outcomes.


    Looking for more sleep disorders discussion? Check out the NeurologyLive® sleep disorders clinical focus page.

    Episode Breakdown:
    • 1:10 – Motivations behind conducting listening analysis
    • 3:15 – Major clinical takeaways from study; notable quality of life impairments in narcolepsy
    • 7:00 – Impact of cataplexy and patients' overreaction
    • 9:50 – Neurology News Minute
    • 12:20 – Reasons for missed and misdiagnosis
    • 14:50 – Early tips to pathing patients towards treatment success

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Grants Traditional Approval to Elevidys Gene Therapy for Ambulatory DMD, Accelerated Approval for Nonambulatory Patients
    • FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
    • FDA Approves Pitolisant for Excessive Daytime Sleepiness in Pediatric Narcolepsy

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    19 m
  • 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

    117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
    Jun 14 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 29-June 2, in Nashville, Tennessee. Those included in this week's episode, in order of appearance, are:

    • Anthony Feinstein, PhD, FRCPC, MBBCh, a professor of psychiatry at the University of Toronto.
    • Brian G. Weinshenker, MD, a professor of neurology at the University of Virginia.
    • Douglas A. Wajda, PhD, an assistant professor of neurology and member of the Health and Human Performance Department in the College of Education at Cleveland State University.
    • Le Hua, MD, director of Clinical Operations and director of the Multiple Sclerosis Program at Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, Nevada.
    • Eion P. Flanagan, MB, BCh, a professor of neurology and chief of the Division of Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic; and director of the Autoimmune Neurology Fellowship.

    Want more from the 2024 CMSC Annual Meeting? Click here for all of NeurologyLive®'s coverage of CMSC 2024.

    Episode Breakdown:
    • 1:40 – Feinstein on the difficulties with improving fatigue in multiple sclerosis and the lack of improvement seen from approved disease-modifying therapies.
    • 5:20 – Weinshenker on the key diagnostic aspects of neuromyelitis optica spectrum disorder and how it differs from other similarly presenting autoimmune disorders.
    • 9:40 – Wajda on the use of the Cionic Neural Sleeve, the advantages it holds, and how it may be used to treat gait dysfunction in multiple sclerosis.
    • 12:00 – Hua on the differential diagnosis of pediatric-onset MS vs late-onset MS, and the notable biologic changes observed.
    • 19:30 – Flanagan on the diagnostic pearls for MOG-antibody associated disease and the importance of early recognition of this group.

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    23 m
  • 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

    116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
    May 31 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Peters, an expert in the field, provided insight on the mechanism of action of vorasidenib, the added value behind the exploratory analysis, and the next steps in research. Furthermore, she provided context on the patient sample observed and why these data may hold significant weight going forward.

    Looking for more neuromuscular discussion? Check out the NeurologyLive® epilepsy clinical focus page.

    Episode Breakdown:
    • 1:05 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor
    • 2:00 – Overview of exploratory analysis results
    • 4:20 – Significance of new data, how it adds to previous primary and secondary outcomes
    • 5:50 – Neurology News Minute
    • 8:25 – Next steps for the study and use of vorasidenib
    • 10:35 – Remaining unmet needs for patients with diffuse gliomas

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
    • Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
    • FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    14 m
  • 114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

    114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development
    May 3 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Justin Klee and Josh Cohen, cofounders and cochief executive officers of Amylyx Pharmaceuticals, sat down at the recently concluded AAN Annual Meeting to discuss the results from the pivotal phase 3 PHOENIX trial (NCT) of AMX0035 (Relyvrio) in patients with amyotrophic lateral sclerosis (ALS). The duo provided clarity on the findings, positive takeaways from the disappointing data, and the lessons learned in ALS drug development. In addition, the two provided commentary on the future plans of the therapy in other tauopathies like progressive supranuclear palsy and neurologic conditions like Wolfram syndrome. Furthermore, Klee and Cohen shared thoughts on the company's drug pipeline, including AMX0114, an antisense oligonucleotide in development for patients with ALS.

    Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

    Episode Breakdown:
    • 1:05 – Decision behind removing AMX0035 from market
    • 3:00 – Lessons from PHOENIX, AMX0035 drug development program
    • 6:45 – Unraveling PHOENIX study data
    • 10:00 – Neurology News Minute
    • 12:10 – Potential of AMX0035 in other tauopathies, neurologic conditions
    • 15:00 – Outlook of antisense oligonucleotide AMX0114 in ALS

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
    • Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
    • FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    20 m